Economics

In the previous installment about the molecular medicine conference, I emphasized that the science of so-called complex, polygenic diseases like cancer is, well, complex. But there are other complications as well in the life science business. Biotechnology and pharmaceuticals are also risky, complicated enterprises from a financial standpoint. In a way it’s kind of a layering of complexities, one atop ...

New York Times columnist Thomas Friedman has commented that America’s answer to offshoring is our innovative and entrepreneurial culture. He says it can’t be duplicated anywhere. With some reservations, I tend to agree with him (some of you may remember our discussion a few months ago of You’re-in-Control at MIT.)

Fast Company has done a retrospective of sorts about the lessons of the “New Economy.” And why not; FC along with Wired, was one of the foremost proponents of the New Economy hype. Their name is ample testimony to that. My impression is the magazine has barely survived the bust. There are some reflections on what the truth turned out ...

I’ve mentioned a couple of times before that drug companies are beginning to move their clinical trials to India and that India is eager to get the business. An article in today’s Wall Street Journal give some insight into this emerging practice.